The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.

Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.

Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.

Top officials want confirmatory trials to finish in a ‘reasonable amount of time’ and worry that ‘if 100% of them were able to confirm, then the bar’s too high.’